The metabolic effects of glucagon on the heart were studied in subjects with and without coronary artery disease. In both groups, a moderate rise in the arterial glucose level occurred with practically unchanged glucose uptake by the myocardium. Myocardial oxygen extraction was also unchanged in both groups of subjects. In individuals with normal coronary arteries, myocardial extraction ratio of lactate was normal before and unchanged after glucagon administration. In patients with significant coronary artery disease, mean extraction ratio of lactate was very low before glucagon and increased markedly following its administration. Seven of 18 patients had production of lactate by the myocardium before glucagon, and this reverted to lactate extraction 5 min after glucagon administration. Left ventricular work index was found to increase more than indices of myocardial contractility and oxygen consuimption, and improved aerobic lactate utilization during glucagon action may be partly related to the lower oxygen cost of work performance or improved cardiac efficiency. Arterial serum potassium level decreased in both groups of subjects after glucagon administration, with the appearance of a slightly negative potassium balance across the myocardium. 
advantages of glucagon in these clinical situations. Firstly, glucagon therapy can be effective despite full digitalization3 8, 11, 12 and does not enhance ventricular irritability.1-12 It acts also after myocardial depletion of catecholamines by previous treatment with reserpine."1 3' 4 It is not antagonized by betareceptor blocking agents.3' 4,7 Duration of action is at least 15 to 20 min,3 8, 9 and tachyphilaxis does not occur.3 Lastly, glucagon is remarkably free of any serious side effects.1- '3 It is not known, however, whether the myocardial oxygen requirements of increased contractility and heart rate, following administration of glucagon, can adversely influence its clinical use. Consequently, some measurable aspects of myocardial metabolism following glucagon administration were investigated, in After completion of the study, percutaneous selective cine coronary arteriography17 was performed in all subjects as part of a diagnostic investigation. Ten individuals were shown to have normal coronary arteries (group A), and 18 patients had significant coronary artery disease (group B). The age range, sex, and severity of disease of the patients are presented in table 1.
Coronary artery disease was considered significant when there was more than 50% narrowing of one or more major branches of the coronary arteries.
Results
The hemodynamic data, pH, oxygen, glucose, and potassium measurements were not significantly different in subjects with normal coronary arteriograms (group A) and in patients with significant coronary artery disease (group B).
Hemodynamic Data
Maximum hemodynamic changes occurred between 2 and 5 min after administration of glucagon. The effects of glucagon decreased progressively in 10 to 15 min. There was often a return to or near to control levels at 15 min (table 2) .
Heart rate and mean aortic pressure rose 12% in group A and 13% in group B. The ability of the left ventricle to perform work, on the other hand, increases more than myocardial oxygen consumption. This, in the presence or absence of coronary heart disease, indicates an improved cardiac efficiency, '7' 19 which is presumably related to better energy or oxygen utilization by the myocardium following glucagon administration.
A moderate rise in blood glucose level and slight drop in serum potassium level, observed in the present study, have been previously shown."1 The hyperglycemia, however, is not responsible for the inotropic effect of glucagon, since the simultaneous administration of insulin in dogs does not alter the positive response.3 Moreover, despite higher arterial levels, glucose and free fatty acid uptake by the myocardium are not increased in dogs. '8 Glucose uptake by the myocardium was also unchanged in our patients following the moderate hyperglycemia induced by glucagon. This is in agreement with previous observations showing that myocardial extraction of glucose no longer increases after arterial glucose level has reached 110 mg%.20' 21 The reduction in serum potassium following administration of glucagon has been attributed to the insulin response to hyperglycemia with subsequent movement of glucose and potassium into cells.
Two very significant observations from our study are (1) a marked improvement of 'myocardial lactate metabolism in patients with significant or severe coronary artery disease, and (2) the occurrence of a negative potassium balance across the myocardium during glucagon action in both groups of subjects studied.
Unchanged myocardial extraction of lactate following glucagon administration has previously been shown in normal individuals13 and also in dogs. ' Catecholamines can also result in a direct increase in phosphorylase activity and glycogenolysis. Glycolysis is enhanced, and it has been shown that, following isoproterenol administration, lactate can accumulate within the myocardium rather than being metabolized. 26 In patients with significant coronary artery disease, the occurrence of anaerobic metabolism and myocardial lactate accumulation and production has been repeatedly shown during infusions of isoproterenol.28 ' 29 It has been well established recently that glucagon does not stimulate alpha3 or betareceptors3' 4 of the heart and blood vessels and that it has no cholinergic action.3 In the intact heart, glucagon probably activates the adenyl cyclase enzyme system through a mechanism 31 The action of glucagon on myocardial contractility and anaerobic metabolism are presumably both secondary to the effects of cyclic AMP in the myocardial cells.32 33 Increased intracellular levels of cyclic AMP can be related to the inotropic effects of glucagon.23 Cyclic AMP also activates phosphorylase to promote glycogenolysis and supply endogenous glucose for substrate utilization. Cyclic AMP also has the ability to enhance glycogen formation in the myocardium in the presence of high arterial glucose level.
It can be postulated that, following interventions on myocardial contractility in patients with restricted coronary circulation, the oxygen cost of work performance or myocardial efficiency directly affects aerobic lactate utilization by the myocardium.
Thus, following glucagon administration, the lower oxygen cost for a given work load of the left ventricle may contribute at least partly to the improved myocardial lactate utilization in patients with coronary artery disease. Previous studies from this laboratory have shown that a similar situation may be obtained during moderate leg exercise. 34 On the other hand, beta-receptor stimulation and electrical stimulation35 of the heart significantly decrease cardiac efficiency and often result in lactate production by the myocardium in patients with coronary artery disease. This occurs despite a marked increase in total coronary blood flow following these inotropic interventions on the heart. The present data suggest that, although glucagon increases myocardial contractility only moderately, it is a more suitable inotropic agent than the beta-adrenergic stimulators, especially in patients with acute and chronic ischemic heart disease.
The higher potassium level in coronary sinus blood, compared to arterial level, is probably not an effect of concentration, since it occurs with a presumed increase in coronary blood flow. This negative potassium balance across the myocardium may well represent Circulation, Volume XLII, July 1970 intracellular replacement of potassium by sodium, like that which follows digitalis administration. It has also been shown that increased cyclic AMP probably influences cardiac inotropism by increasing the intramyocardial calcium pool and cellular membrane permeability.23 As is well known, calcium is needed for excitation-contraction coupling and has a major role in increased contractility.
This inotropic mechanism of glucagon, however, appears to differ from that of digitalis glycosides in many respects. Glucagon does not block adenosine triphosphatase (ATPase) activity at the cell membrane and has been shown not to have any competitive effect with digitalis preparations. Also, this potassium loss is not accompanied by increased irritability of the myocardium.
